TABLE 3.
Phasea | Mean value (SD)b
|
|||||||
---|---|---|---|---|---|---|---|---|
Total drug concn data |
Free drug concn data |
|||||||
AUC0–24 (mg · h/liter) | kel (h−1) | V (liters) | CL (liters/h) | AUC0–24 (mg · h/liter) | kel (h−1) | V (liters) | CL (liters/h) | |
1 | 26.9 (3.2) B | 0.9 (0.3) | 28.7 (7.3) B | 25.0 (3.7) B | 16.0 (2.3) B | 1.2 (0.4) | 38.4 (9.4) | 42.3 (7.5) B |
2 | 24.8 (7.4) C | 1.2 (0.4) | 26.8 (11.2) C | 28.8 (8.2) C | 14.5 (4.7) C | 1.2 (0.4) | 42.1 (14.2) | 49.9 (15.2) C |
3 | 78.0 (16.1) | 0.8 (0.1) | 10.6 (1.8) | 8.9 (2.2) | 25.5 (6.4) | 0.9 (0.2) | 30.5 (7.8) | 27.6 (7.4) |
Phase 1, normoalbuminemia; phase 2, hypoalbuminemia; phase 3, albumin replacement.
AUC0–24, area under the concentration-time curve during a 24-h period; CL, clearance; kel, elimination constant; V, volume of distribution; B, significant difference (P < 0.05) between phases 1 and 3; C, significant difference (P < 0.05) between phases 2 and 3.